Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13335MR)

This product GTTS-WQ13335MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13335MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8853MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ8497MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ7180MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ4080MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ11896MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ4904MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ15802MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11576MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MG-A271
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW